Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions The Panic-Proof Portfolio (Stockchase Research)
Haemonetics CorporationHAEPAST TOP PICKNov 09, 2021
(A Top Pick May 18/21, Up 6.23%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HAE, has triggered its stop at $60. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.
$58.27
Stock price when the opinion was issued
$78.20
As of Jun 12, 2026. Market Open.
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly HAE stock prices took a hit in April when they announced a key client would not be renewing in 2022. The blood and plasma services company provides collection devices, disposables and software solutions. As treatments and collections resume normal activity levels post-pandemic, it is anticipated growth will return to the company. It trades at 28x earnings, compared to peers over 41x. Over 95% of the stock is held by large institutions, allowing for greater staying power. We would purchase this with stop loss at $40, looking to achieve $98 -- upside potential over 70%. Yield 0% (Analysts’ price target is $97.33)
Healthcare
